Journal of Young Pharmacists logo
Submit
Journal of Young PharmacistsACADEMIC PUBLISHING
Article

Clinical Evaluation of T-AYU-HM Premium in Sickle Cell Disease (HbSS) Patients: A Retrospective Study

1★, 1, 1, 1, 2★ Corresponding author

  1. 1Dhanvantari Clinic, Ayurveda Healthcare and Research Centre, Vyara, Gujarat, INDIA.
  2. 2Department of Pharmacology, ROFEL Shri G M Bilakhia College of Pharmacy, Vapi, Gujarat, INDIA.

CORRESPONDENCE

Atul M Desai

Dhanvantari Clinic, Ayurveda Healthcare and Research Centre, Vyara, Gujarat, INDIA.

dratuldesai@rediffmail.com

Received: 24-01-2024; Revised: 05-02-2024; Accepted: 01-03-2024.

Volume 16, Issue 2 · pp. 301-307 · 2024 · DOI: 10.5530/jyp.2024.16.38

ABSTRACT

Background: Sickle cell disease (HbSS) is one of the main hemoglobinopathies that affect the indigenous tribes and is a significant cause of morbidity and mortality. The effectiveness and safety of alternative medicines for sickle cell disease patients require further scientific study. The proposed study was conducted to clinically evaluate the safety and effectiveness of T-AYU-HM Premium Tablet (300 mg).Materials and Methods: This is a single-arm observational retrospective cohort study of 100 sickle cell disease subjects. Based on inclusion and exclusion criteria, the clinical and vital information of the patients was acquired, assessed, and reported. A follow-up period of 120±10 days was deemed sufficient. Data were analysed using a statistical package for the social sciences (SPSS).Results: The levels of haemoglobin (g/dL) (9.43±1.83 to 10.11±1.37) and red blood cells (/mm3) (3.89±0.81 to 4.18±0.64) were significantly improved (p<0.05). Reticulocyte count (%) changed significantly from 4.51±3.20 to 2.84±2.34. The number of blood transfusions (7.12±26.80 to 00) and the percentage of hospitalisations (76% to 00) that occurred more than six times prior to presentation were significantly reduced.Conclusion: In this retrospective analysis, there were no reported adverse consequences. Patient’s responses and all the clinical parameters like haematology, liver function parameters, clinical, and pain-associated symptoms with the disorder showed T-AYU-HM Premium to be an effective and safer therapy in the treatment of sickle cell anemia. Further well-planned interventional studies may become useful to justify the same.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Desai, A. M., A, D. K., Hemshree, D., A, D. R., & K, D. C. (2024). Clinical Evaluation of T-AYU-HM Premium in Sickle Cell Disease (HbSS) Patients: A Retrospective Study. Journal of Young Pharmacists, 16(2), 301-307. https://doi.org/10.5530/jyp.2024.16.38

    Copyright and licence

    © 2024 Author(s)

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. CC BY-NC-SA 4.0